Ve-ptp knockout
AssigneeMannin Research Inc.
InventorSusan QUAGGIN
Life of this patent
Estimating the term…
Abstract
This invention relates to glaucoma, and more particularly to use of VE-PTP-null allele to rescue from the glaucoma symptom of elevated intraocular pressure. This invention also relates to conditional knockout of VE-PTP to rescue from the glaucoma symptom of elevated intraocular pressure expressed in an Angiopoietin 1 and Angiopoietin 2 conditional knockout mouse. This invention also relates to the use of VE-PTP-null alleles.
Claims11
A method of producing a mouse with reduced VE-PTP, comprising replacing at least one wild type VE-PTP allele with a VE-PTP-null allele.
The use of a VE-PTP-null allele introduced in a Tie2 heterozygous mouse to decrease phenotypic expression of high intraocular pressure.
A VE-PTP-null allele.
A mouse model comprising a mouse with a conditional triple knockout of Angiopoietin 1, Angiopoietin 2 and VE-PTP.
A mouse model comprising a mouse with a conditional complete knockout of VE-PTP.
A method of producing a conditional triple knockout mouse, comprising replacing both wild type VE-PTP alleles with VE-PTP-null alleles in an Ang1/2 conditional knockout mouse.
A method of producing a VE-PTP conditional knockout mouse comprising replacing both wild type VE-PTP alleles with VE-PTP-null alleles in a mouse.
The use of VE-PTP-null alleles to decrease high intraocular pressure in an Ang1/2 conditional knockout mouse.
The use of VE-PTP-null alleles to decrease high intraocular pressure in a mouse expressing a phenotype of high intraocular pressure.
The use of VE-PTP-null alleles in an Ang1/2 conditional knockout mouse to eliminate phenotypic expression of high intraocular pressure.
Dependencies are inferred from the claim text.